BACKGROUND: Epidemiological studies have suggested that soybean isoflavones are associated with a lower risk of prostate cancer. However, the mechanisms of prostate cancer prevention by soybean isoflavones have yet to be fully clarified. METHODS: Two soybean isoflavones (genistein and daidzein) and their glucosides (genistin and daidzin) were tested for their effects on cell growth and apoptosis of the LNCaP human prostatic cancer cell line. RESULTS: Among these isoflavones, genistein was found to inhibit the growth of LNCaP most effectively, with an IC50 value of 40 microM. The inhibition of cell growth by genistein was accompanied by the suppression of DNA synthesis and the induction of apoptosis. Expression of prostate-specific antigen (PSA) in LNCaP was also significantly reduced by the treatment with genistein. CONCLUSIONS: The results suggest that genistein might primarily influence human prostate cancer development by reducing tumor growth.
BACKGROUND: Epidemiological studies have suggested that soybeanisoflavones are associated with a lower risk of prostate cancer. However, the mechanisms of prostate cancer prevention by soybeanisoflavones have yet to be fully clarified. METHODS: Two soybeanisoflavones (genistein and daidzein) and their glucosides (genistin and daidzin) were tested for their effects on cell growth and apoptosis of the LNCaP humanprostatic cancer cell line. RESULTS: Among these isoflavones, genistein was found to inhibit the growth of LNCaP most effectively, with an IC50 value of 40 microM. The inhibition of cell growth by genistein was accompanied by the suppression of DNA synthesis and the induction of apoptosis. Expression of prostate-specific antigen (PSA) in LNCaP was also significantly reduced by the treatment with genistein. CONCLUSIONS: The results suggest that genistein might primarily influence humanprostate cancer development by reducing tumor growth.
Authors: Florastina Payton-Stewart; Norberta W Schoene; Young S Kim; Matthew E Burow; Thomas E Cleveland; Stephen M Boue; Thomas T Y Wang Journal: Mol Carcinog Date: 2009-09 Impact factor: 4.784
Authors: Nesma A Z Sarhan; Ezzeldein S El-Denshary; Nabila S Hassan; Ferial M Abu-Salem; Mosaad A Abdel-Wahhab Journal: ISRN Pharmacol Date: 2012-03-01